Lubin Investment · Blog

Should you buy Monster Beverage (MNST) stock in 2026?

2026-07-19 ·

MNST: see the full analysis on Lubin Investment

Monster Beverage is a high-quality business, one of the best scores in my filter, driven by double-digit international growth and a Coca-Cola distribution deal that locks up its market. But the stock trades today near the priciest point of its last five years, barely above my fair buy price. A great business at a price that leaves almost no room for error: here's how I see it.

The Monster paradox: sales are soaring, the stock is doubting itself

In the first quarter of 2026, Monster Beverage posted numbers that, on paper, look more like a startup's than those of a beverage giant over thirty years old: net sales up 26.9% to $2.35 billion, net income up 28.6%. And yet, for months, a shadow has hung over the entire sugary drinks sector: GLP-1 drugs (Ozempic, Wegovy and their peers), designed to cut appetite, and along with it, the craving for sugar.

This is exactly the kind of situation my method is built to untangle. On one side, a company that checks nearly every box of financial quality. On the other, a very real market fear weighing on the stock. As always, I separate the two questions: is this a good business? And, independently, is this the right price today?

A cash machine that passes 9 out of 10 criteria

My filter runs every company through ten concrete financial criteria, no intuition or opinion involved. Monster passes nine. Net margin comes in at 23.1%, and free cash flow margin (the cash that's actually left over once every bill is paid) at 22%. In other words, out of every $100 of sales, $22 ends up as cash truly available to the company, a level most consumer goods companies never reach. Cash return on capital employed hits 39.7%, a number that says every dollar reinvested in the business generates far more in return.

The one criterion that clearly fails in my filter is margin expansion: over five years, Monster's costs have grown slightly faster than its revenue, due to rising aluminum can and freight costs, plus a geographic mix that weighs on gross margin (down from 56.5% to 55.0% year over year). That's not a red flag: it's the price of fast international expansion, where every new market carries its own cost structure before reaching the scale of legacy markets.

The real engine: international growth, powered by a deal worth its weight in gold

What stands out this quarter isn't the US, it's the rest of the world. International sales jumped 44.9% to $1.06 billion, now 45% of total revenue. EMEA grew 53% in dollars, Asia Pacific 40%, with standout performances in China (+95%) and India (+95%).

It's no accident these markets are ramping this fast: since late 2025, Monster has leaned on a reinforced Coca-Cola distribution agreement, opening a logistics network present in over 160 countries. That's exactly what a moat is (a competitive trench that protects a company from a rival trying to take its place): no independent energy-drink challenger can replicate overnight the trucks, warehouses, and shelf space Coca-Cola puts at Monster's disposal. With roughly 39% of the global energy drink market, just behind Red Bull (43%), Monster and Red Bull form a duopoly that newer entrants (Celsius, Ghost) nibble at the edges of, without ever threatening the market structure.

Management is sending a consistent signal too: a new $500 million buyback program was approved this quarter, on top of $100 million already used this year. Over five years, shares outstanding have shrunk 7.55% a year, mechanically boosting free cash flow per share, one reason earnings per share have grown 31.5% a year over the period, far faster than sales.

The market's fear: will GLP-1 drugs kill sugary drinks?

The bear case fits in one sentence: GLP-1 drugs cut appetite, including cravings for sugar and empty calories, and energy drinks fall into that category. Sector studies estimate the impact of these drugs on US food and beverage demand at around -0.2% of volume per year through 2031, a real but modest penalty, far from a collapse.

And Monster's numbers, for now, contradict the doomsday scenario: energy segment sales grew 27.6% in the first quarter. One possible explanation: GLP-1 users cut back on alcohol and excess caloric food, but energy drinks answer a different need, alertness and performance, not pure indulgence. Some brands are even launching protein- or electrolyte-enriched versions aimed at this crowd. The GLP-1 risk is real and worth watching quarter after quarter, but today it remains a market worry, not a measured fact in Monster's books.

The price: a stock approaching its priciest valuation in 5 years

To judge whether a price is expensive, I never just compare a stock to the market in the abstract: I compare it to itself. Monster's P/FCF (price-to-free-cash-flow, the stock price divided by the cash it generates each year) stands today at 49.7 times. Over its last five years, this multiple has historically sat lower: today's level ranks in the 77th percentile of its own history, meaning it's pricier than three quarters of trading days over the past five years.

Compared to its sector (non-alcoholic beverages), it's even tighter: the sector median runs around 27.4 times, and Monster ranks in the 92nd percentile, pricier than nearly all its peers, including Coca-Cola (27.8x), PepsiCo (22.7x), or Keurig Dr Pepper (28.1x). The market is paying a clear premium for Monster's international growth, which isn't unreasonable given the pace of the numbers, but it leaves little room for disappointment.

My model calculates a fair buy price of $97.07 for Monster, based on current free cash flow per share and a conservative exit multiple consistent with its quality. The current price, $97.50, sits barely 0.4% above that target. In other words, Monster is neither a bargain nor a folly: it trades almost exactly at what I consider a fair price, which is already rare for a business of this quality.

How I make the call, without emotion

Monster's quality isn't in question: a distribution moat, exceptional return on capital, double-digit international growth, massive buybacks. The real question is the price. At 49.7 times free cash flow, near its own 5-year record for expensiveness and pricey versus peers, the stock offers almost no margin of safety: it's fundamentally fairly valued, neither cheap nor in a bubble.

If you believe international growth (China, India, EMEA) can keep this pace for several more years, this price, sitting almost exactly at my target, is justified. If you think GLP-1 fears will eventually bite into volumes, or that the aluminum and freight margin squeeze will persist, it's better to wait for a real pullback than to buy at a break-even price. I don't take a position for you: I set a price, and I wait for it to come to me or below, never above.

FAQ

Why does Monster Beverage score 9 out of 10 in the quality filter?

Because it passes nearly every financial criterion I consider essential: profitability, sales and free cash flow growth, buybacks, return on capital employed, no net debt. The one failing criterion is margin expansion, temporarily squeezed by aluminum and freight costs plus international expansion.

Will GLP-1 drugs (Ozempic, Wegovy) hurt Monster's sales?

It's the risk most cited by the market. Sector studies estimate the impact on beverage demand at around -0.2% of volume per year in the US, a modest effect. Monster's current numbers (+27.6% in the energy segment) show no sign of slowdown from this factor so far, but it's worth watching quarter after quarter.

What does the Coca-Cola deal actually change for Monster?

Coca-Cola distributes Monster's products in over 160 countries through its global logistics network (trucks, warehouses, retail agreements). It's an advantage no independent competitor can replicate quickly, which explains the 44.9% growth in international sales this quarter.

Is a 49.7x P/FCF a good entry point?

My model calculates a fair buy price of $97.07, and the current price ($97.50) is nearly aligned with it. The stock is neither a bargain nor overvalued: it trades close to its fair price. This is not investment advice, do your own research.

MNST: see the full analysis on Lubin Investment

About the author

Written by Lubin Danilo, founder of Lubin Investment. A self-taught individual investor, I find fundamental analysis fascinating, and it has delivered excellent results. For three years now, my performance has beaten the S&P 500. But analyzing every stock took too much time: sites with incomplete data, calculation methods and criteria never aligned with mine. And spotting the best stocks was just as time-consuming, even with my own well-defined checklist. So I put my software development background to work to build this software, base my investment strategy on its results, and share it with people who share the same passion as me. It judges a company's quality and its price separately, using criteria drawn from the financial literature (Warren Buffett, Michael Mauboussin, Aswath Damodaran).